Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | AR | P10275 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.59 |
| ▸ | PGR | P06401 | 3/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | SNCA | P37840 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274070 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL9172697 | 1.00 | SHBG (1.00) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL1682762 | 0.88 | SHBG (0.79) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL22100655 | 0.88 | SHBG (0.79) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL21850133 | 0.88 | SHBG (0.79) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL2545773 | 0.88 | SHBG (0.79) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL11427198 | 0.86 | SHBG (0.76) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL11427195 | 0.86 | SHBG (0.76) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| Clostebol SCHEMBL4437252 | 0.86 | SHBG (0.76) | SHBGCYP3A4CYP19A1HSD17B10AR | |
| SCHEMBL10944734 | 0.86 | SHBG (0.76) | SHBGCYP3A4CYP19A1HSD17B10AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101861328-B | Aminooximes of 2-and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular diseases | SIGMA TAU IND FARMACEUTI | 2014-08-13 | — | — | CN | disclosed |
| US-8664210-B2 | Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2014-03-04 | — | — | US | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2209795-B1 | AMINOOXIME DERIVATIVES OF 2- AND/OR 4-SUBSTITUTED ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA TAU IND FARMACEUTI (IT) | 2013-04-24 | — | — | EP | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-20100324003-A1 | AMINOOXIME DERIVATIVES OF 2- AND/OR 4-SUBSTITUTED ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-23 | — | — | US | disclosed |
| CN-101861328-A | Amines of 2-and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular diseases | SIGMA TAU IND FARMACEUTI | 2010-10-13 | — | — | CN | disclosed |
| EP-2209795-A1 | AMINOOXIME DERIVATIVES OF 2- AND/OR 4-SUBSTITUTED ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009047101-A1 | AMINOOXIME DERIVATIVES OF 2- AND/OR 4-SUBSTITUTED ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-04-16 | — | — | WO | disclosed |
| WO-2006081658-A1 | IN SILICO SCREENING FOR SHBG BINDING LIGANDS VIA PHARMACOPHORE MODELS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2006-08-10 | — | — | WO | disclosed |
| US-5157031-A | Androsterone derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0133995-B1 | STEROIDS AND THERAPEUTIC COMPOSITIONS CONTAINING SAME | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-04-15 | — | — | EP | disclosed |
| EP-0246650-B1 | STEROIDS USEFUL AS ANTI-CANCER AND ANTI-OBESITY AGENTS, A THERAPEUTIC COMPOSITION CONTAINING THEM AND USE THEREOF FOR THE PREPARATION OF A THERAPEUTIC COMPOSITION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-01-02 | — | — | EP | disclosed |
| US-5028631-A | Anticancer, antiobesity, anticholesterol | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1991-07-02 | — | — | US | disclosed |
| EP-0423842-A2 | Steroids and therapeutic compositions containing same | Research Corporation (US) | 1991-04-24 | — | — | EP | disclosed |
| US-5001119-A | 16-substituted androstanes and 16-substituted androstenes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1991-03-19 | — | — | US | disclosed |
| US-4898694-A | 17-Hydroxy-steroids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1990-02-06 | — | — | US | disclosed |
| EP-0246650-A1 | Steroids useful as anti-cancer and anti-obesity agents, a therapeutic composition containing them and use thereof for the preparation of a therapeutic composition | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1987-11-25 | — | — | EP | disclosed |
| EP-0133995-A2 | Steroids and therapeutic compositions containing same | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1985-03-13 | — | — | EP | disclosed |
| US-4160027-A | OXYTOCICS, 4A,5A-EPOXY-2A-CYANO-3-OXOSTEROIDES, STEROIDO(2,3-O)ISOOXAZOLES | STERLING DRUG INC. (US) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324003-A1 | AMINOOXIME DERIVATIVES OF 2- AND/OR 4-SUBSTITUTED ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | CYP11B2, CYP11B1, SRD5A2 | SHBG 16/4885CYP3A4 34/4885CYP19A1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.